Leukemia ECOG 2905

March 13, 2013

Location: The Hospital of Central Connecticut

A Randomized Phase III Trial Comparing the Frequency of Major Erythroid Response (MER) to Treatment with Lenalidomide (Revlimid) Alone and in Combination with Epoetin Alfa (Procrit) in Subjects with Low- or Intermediate-1 Risks MDS and Symptomatic Anemia – temporarily suspended to accrual.

Connect With Us

Subscribe to Our Newsletters

Get the latest healthcare news directly in your inbox.

Hartford HealthCare Offices

One State Street, Suite 19, Hartford, CT 06103 • Contact Us

Donations to Hartford HealthCare are managed by the Hartford Hospital Department of Philanthropy, a Connecticut tax-exempt organization under section 501(c)(3) of the IRS code (E.I.N. 06-0646668). For more information, click here.